fluoxetine has been researched along with Nausea in 34 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Nausea: An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fluoxetine, a specific serotonin reuptake inhibitor, was compared to amitriptyline in the treatment of 51 outpatients with primary major depressive disorder." | 9.05 | A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder. ( Chouinard, G, 1985) |
| "The efficacy and safety of fluoxetine, a new antidepressant agent, were assessed in a double-blind, parallel, randomized study of 44 outpatients with major depressive disorder." | 9.05 | A comparative trial of fluoxetine and amitriptyline in patients with major depressive disorder. ( Feighner, JP, 1985) |
| "The incidence of treatment-emergent nausea during 6-month continuation of duloxetine treatment (80 mg/d, 2." | 6.71 | Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine. ( Greist, J; Mallinckrodt, CH; McNamara, RK; Raskin, J; Rayamajhi, JN, 2004) |
| "Fluoxetine was compared to doxepin in geriatric out-patients with major depressive illness." | 6.66 | Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. ( Cohn, JB; Feighner, JP, 1985) |
| "There is low-certainty evidence to suggest that metformin may be effective in preventing weight gain." | 5.22 | Pharmacological interventions for prevention of weight gain in people with schizophrenia. ( Agarwal, SM; Ahsan, ZA; Cohn, T; Duncan, MJ; Faulkner, GEJ; Hahn, M; Lockwood, JT; Remington, G; Stogios, N; Takeuchi, H; Taylor, VH, 2022) |
| "Common adverse events associated with initiating fluoxetine treatment in depressed patients, including nausea, insomnia, nervousness, and somnolence, resolve in the majority of patients and become significantly less frequent with continued treatment over a 6-month period." | 5.09 | Changes in adverse events reported by patients during 6 months of fluoxetine therapy. ( Amsterdam, JD; Beasley, CM; Michelson, D; Quitkin, FM; Reimherr, FW; Rosenbaum, JF; Sundell, KL; Tamura, RN; Zajecka, J, 1999) |
| "This randomized, double-blind, parallel-group design study of 100 outpatients with major depressive disorder is the first study in the United States to compare the efficacy and tolerability of fluvoxamine (100-150 mg/day) and fluoxetine (20-80 mg/day)." | 5.08 | A comparison of fluvoxamine and fluoxetine in the treatment of major depression. ( Bradford, D; Coccaro, E; Fabre, L; Holland, P; Perse, T; Rapaport, M; Sheline, Y, 1996) |
| "Fluoxetine, a specific serotonin reuptake inhibitor, was compared to amitriptyline in the treatment of 51 outpatients with primary major depressive disorder." | 5.05 | A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder. ( Chouinard, G, 1985) |
| "The effect of dose frequency on fluoxetine efficacy and safety was evaluated in a double-blind study in patients with major depressive disorder." | 5.05 | Comparison of two dosage regimens of fluoxetine in major depression. ( Amsterdam, JB; Glaudin, V; Rickels, K; Settle, GP; Smith, WT; Weise, C, 1985) |
| "The efficacy and safety of fluoxetine, a new antidepressant agent, were assessed in a double-blind, parallel, randomized study of 44 outpatients with major depressive disorder." | 5.05 | A comparative trial of fluoxetine and amitriptyline in patients with major depressive disorder. ( Feighner, JP, 1985) |
| "The potential of the selective serotonin reuptake inhibitor (SSRI), fluoxetine (which produces nausea in the clinic), to produce conditioned gaping in rats and of the 5-HT(3) antagonists (ondansetron and palonosetron) and the 5-HT(1A) autoreceptor agonist (8-OH-DPAT) to reverse this effect were evaluated." | 3.75 | Effect of 5-HT3 antagonists and a 5-HT(1A) agonist on fluoxetine-induced conditioned gaping reactions in rats. ( Limebeer, CL; Litt, DE; Parker, LA, 2009) |
| "The side effect profile and safety of fluoxetine are reviewed." | 3.75 | The side effect profile and safety of fluoxetine. ( Wernicke, JF, 1985) |
| "To assess whether fluoxetine use is associated with significant weight loss or other side effects in depressed elderly patients with concomitant medical illness." | 3.68 | Fluoxetine in elderly patients: is there cause for concern? ( Brymer, C; Winograd, CH, 1992) |
| " The present study investigated potential modifications to the pharmacokinetic profile of milnacipran at steady-state when it is substituted for fluoxetine without any washout period." | 2.72 | Lack of pharmacokinetic interaction when switching from fluoxetine to milnacipran. ( Chassard, D; Hermann, P; Puozzo, C, 2006) |
| "The incidence of treatment-emergent nausea during 6-month continuation of duloxetine treatment (80 mg/d, 2." | 2.71 | Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine. ( Greist, J; Mallinckrodt, CH; McNamara, RK; Raskin, J; Rayamajhi, JN, 2004) |
| "Zolmitriptan was well tolerated when given alone or concomitantly with fluoxetine." | 2.69 | Zolmitriptan (311C90) does not interact with fluoxetine in healthy volunteers. ( Cleary, EW; Huffman, CS; Polvino, WJ; Smith, DA; Watkins, S, 1998) |
| " There were 188 adverse events: insomnia, dizziness, headache, nausea, dry mouth and myoclonic jerks were the most common." | 2.68 | Safety and tolerability of combined treatment with moclobemide and SSRIs: a systematic study of 50 patients. ( Hawley, CJ; McPhee, S; Pattinson, HA; Quick, SJ; Ratnam, S, 1996) |
| "Fluoxetine was well tolerated during both 24-week continuation periods." | 2.67 | Continuation treatment of OCD: double-blind and open-label experience with fluoxetine. ( Birkett, M; Genduso, L; Koran, L; Tollefson, GD, 1994) |
| "or fluoxetine p." | 2.67 | Efficacy and safety of morning versus evening fluoxetine administration. ( Beasley, CM; Bosomworth, JC; Usher, RW, 1991) |
| "Fluoxetine was compared to doxepin in geriatric out-patients with major depressive illness." | 2.66 | Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. ( Cohn, JB; Feighner, JP, 1985) |
| " We hypothesized that in patients taking 20 mg/day, efficacy would be maintained but the incidence of adverse events would be lower." | 2.41 | Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: a meta-analysis of the 20-mg/day dose. ( Beasley, CM; Gonzales, JS; Koke, SC; Nilsson, ME, 2000) |
| "Fluoxetine is an antidepressant drug with a unique chemical configuration which enhances serotoninergic transmission by inhibiting serotonin uptake." | 2.38 | Fluoxetine: prescribing guidelines for the newest antidepressant. ( Lippmann, S; Pary, R; Tobias, C, 1989) |
| "A side-effect symptom checklist was completed by participants prior to commencing treatment and during treatment (weekly/fortnightly)." | 1.51 | Adverse events reported by anxious school refusing adolescents receiving cognitive behavioral therapy with and without fluoxetine. ( Dudley, AL; Finnin, L; Gordon, MS; Klimkeit, EI; Melvin, GA; Taffe, J; Tonge, B, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (23.53) | 18.7374 |
| 1990's | 16 (47.06) | 18.2507 |
| 2000's | 8 (23.53) | 29.6817 |
| 2010's | 1 (2.94) | 24.3611 |
| 2020's | 1 (2.94) | 2.80 |
| Authors | Studies |
|---|---|
| Agarwal, SM | 1 |
| Stogios, N | 1 |
| Ahsan, ZA | 1 |
| Lockwood, JT | 1 |
| Duncan, MJ | 1 |
| Takeuchi, H | 1 |
| Cohn, T | 1 |
| Taylor, VH | 1 |
| Remington, G | 1 |
| Faulkner, GEJ | 1 |
| Hahn, M | 1 |
| Melvin, GA | 1 |
| Finnin, L | 1 |
| Taffe, J | 1 |
| Dudley, AL | 1 |
| Klimkeit, EI | 1 |
| Gordon, MS | 1 |
| Tonge, B | 1 |
| Limebeer, CL | 1 |
| Litt, DE | 1 |
| Parker, LA | 1 |
| Greist, J | 1 |
| McNamara, RK | 1 |
| Mallinckrodt, CH | 1 |
| Rayamajhi, JN | 1 |
| Raskin, J | 1 |
| Puozzo, C | 1 |
| Hermann, P | 1 |
| Chassard, D | 1 |
| Menza, MA | 1 |
| Dobkin, RD | 1 |
| Marin, H | 1 |
| Martenyi, F | 1 |
| Brown, EB | 1 |
| Caldwell, CD | 1 |
| Tollefson, GD | 1 |
| Birkett, M | 1 |
| Koran, L | 1 |
| Genduso, L | 1 |
| De Wilde, J | 1 |
| Spiers, R | 1 |
| Mertens, C | 1 |
| Bartholomé, F | 1 |
| Schotte, G | 1 |
| Leyman, S | 1 |
| Patris, M | 1 |
| Bouchard, JM | 1 |
| Bougerol, T | 1 |
| Charbonnier, JF | 1 |
| Chevalier, JF | 1 |
| Clerc, G | 1 |
| Cyran, C | 1 |
| Van Amerongen, P | 1 |
| Lemming, O | 1 |
| Høpfner Petersen, HE | 1 |
| Rapaport, M | 1 |
| Coccaro, E | 1 |
| Sheline, Y | 1 |
| Perse, T | 1 |
| Holland, P | 1 |
| Fabre, L | 1 |
| Bradford, D | 1 |
| Menting, JE | 1 |
| Honig, A | 1 |
| Verhey, FR | 1 |
| Hartmans, M | 1 |
| Rozendaal, N | 1 |
| de Vet, HC | 1 |
| van Praag, HM | 1 |
| Hawley, CJ | 1 |
| Quick, SJ | 1 |
| Ratnam, S | 1 |
| Pattinson, HA | 1 |
| McPhee, S | 1 |
| Haddad, P | 1 |
| Zajecka, J | 2 |
| Tracy, KA | 1 |
| Mitchell, S | 1 |
| Zisook, S | 1 |
| Peterkin, J | 1 |
| Goggin, KJ | 1 |
| Sledge, P | 1 |
| Atkinson, JH | 1 |
| Grant, I | 1 |
| Benazzi, F | 1 |
| Smith, DA | 1 |
| Cleary, EW | 1 |
| Watkins, S | 1 |
| Huffman, CS | 1 |
| Polvino, WJ | 1 |
| Wheatley, DP | 1 |
| van Moffaert, M | 1 |
| Timmerman, L | 1 |
| Kremer, CM | 1 |
| Amsterdam, JD | 1 |
| Quitkin, FM | 1 |
| Reimherr, FW | 1 |
| Rosenbaum, JF | 1 |
| Tamura, RN | 1 |
| Sundell, KL | 1 |
| Michelson, D | 1 |
| Beasley, CM | 3 |
| Erjavec, MK | 1 |
| Coda, BA | 1 |
| Nguyen, Q | 1 |
| Donaldson, G | 1 |
| Risler, L | 1 |
| Shen, DD | 1 |
| Nilsson, ME | 1 |
| Koke, SC | 1 |
| Gonzales, JS | 1 |
| Brymer, C | 1 |
| Winograd, CH | 1 |
| Usher, RW | 1 |
| Bosomworth, JC | 1 |
| Hansen, TE | 1 |
| Dieter, K | 1 |
| Keepers, GA | 1 |
| Pary, R | 1 |
| Tobias, C | 1 |
| Lippmann, S | 1 |
| Altamura, AC | 1 |
| Montgomery, SA | 1 |
| Wernicke, JF | 2 |
| Steiner, W | 1 |
| Fontaine, R | 1 |
| Feighner, JP | 2 |
| Cohn, JB | 1 |
| Chouinard, G | 1 |
| Rickels, K | 1 |
| Smith, WT | 1 |
| Glaudin, V | 1 |
| Amsterdam, JB | 1 |
| Weise, C | 1 |
| Settle, GP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Comparison of Bupropion SR and Placebo for Smoking Cessation[NCT00176449] | Phase 4 | 52 participants (Actual) | Interventional | 2001-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for fluoxetine and Nausea
| Article | Year |
|---|---|
Pharmacological interventions for prevention of weight gain in people with schizophrenia.
Topics: Antipsychotic Agents; Betahistine; Famotidine; Fluoxetine; Humans; Melatonin; Metformin; Nausea; Niz | 2022 |
Newer antidepressants and the discontinuation syndrome.
Topics: Adverse Drug Reaction Reporting Systems; Cyclohexanols; Dizziness; Fluoxetine; Headache; Humans; Inc | 1997 |
Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review.
Topics: 1-Naphthylamine; Adolescent; Adult; Child; Clinical Trials as Topic; Cyclohexanols; Dizziness; Femal | 1997 |
Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: a meta-analysis of the 20-mg/day dose.
Topics: Adult; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Female; Fluoxetine; H | 2000 |
Fluoxetine: prescribing guidelines for the newest antidepressant.
Topics: Depressive Disorder; Drug Evaluation; Drug Interactions; Fluoxetine; Humans; Nausea; Serotonin Antag | 1989 |
The side effect profile and safety of fluoxetine.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents, Tricyclic; Cardiovascular Diseases; Clinical | 1985 |
21 trials available for fluoxetine and Nausea
| Article | Year |
|---|---|
Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antidepressive Agents; Antidepressive Agent | 2004 |
Lack of pharmacokinetic interaction when switching from fluoxetine to milnacipran.
Topics: Adult; Area Under Curve; Cyclopropanes; Cytochrome P-450 CYP2D6; Drug Administration Schedule; Drug | 2006 |
An open-label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antidepressive Agents, Second-Generation; Antipsyc | 2007 |
Failed efficacy of fluoxetine in the treatment of posttraumatic stress disorder: results of a fixed-dose, placebo-controlled study.
Topics: Adult; Antidepressive Agents, Second-Generation; Diagnostic and Statistical Manual of Mental Disorde | 2007 |
Continuation treatment of OCD: double-blind and open-label experience with fluoxetine.
Topics: Adolescent; Adult; Aged; Diarrhea; Dose-Response Relationship, Drug; Double-Blind Method; Drug Admin | 1994 |
A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients.
Topics: Adolescent; Adult; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middl | 1993 |
Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Citalopram; Depressive Disorder; Female; Fluoxetine; | 1996 |
A comparison of fluvoxamine and fluoxetine in the treatment of major depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety; Depressive Disorder; Double-Blind Method; | 1996 |
Safety and tolerability of combined treatment with moclobemide and SSRIs: a systematic study of 50 patients.
Topics: Adult; Benzamides; Depressive Disorder; Drug Therapy, Combination; Female; Fluoxetine; Headache; Hum | 1996 |
Treatment of major depression in HIV-seropositive men. HIV Neurobehavioral Research Center Group.
Topics: Adult; Combined Modality Therapy; Comorbidity; Depressive Disorder; Double-Blind Method; Drug Admini | 1998 |
Zolmitriptan (311C90) does not interact with fluoxetine in healthy volunteers.
Topics: Adolescent; Adult; Cranial Sinuses; Cross-Over Studies; Dizziness; Drug Interactions; Drug Tolerance | 1998 |
Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Tricyclic; Depressive Disorder; Drug Administration | 1998 |
Changes in adverse events reported by patients during 6 months of fluoxetine therapy.
Topics: Anxiety; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Fluoxetine; Follow- | 1999 |
Morphine-fluoxetine interactions in healthy volunteers: analgesia and side effects.
Topics: Adult; Analgesia; Analgesics, Opioid; Drug Synergism; Fluoxetine; Humans; Morphine; Nausea; Selectiv | 2000 |
Efficacy and safety of morning versus evening fluoxetine administration.
Topics: Adolescent; Adult; Akathisia, Drug-Induced; Circadian Rhythm; Depressive Disorder; Double-Blind Meth | 1991 |
The evidence for 20mg a day of fluoxetine as the optimal dose in the treatment of depression.
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Depressive Disorder; Dose-Response Relationship, | 1988 |
The side effect profile and safety of fluoxetine.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents, Tricyclic; Cardiovascular Diseases; Clinical | 1985 |
Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder.
Topics: Age Factors; Aged; Anxiety; Blood Pressure; Body Weight; Clinical Trials as Topic; Depressive Disord | 1985 |
A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder.
Topics: Adult; Ambulatory Care; Amitriptyline; Anxiety; Body Weight; Clinical Trials as Topic; Depressive Di | 1985 |
Comparison of two dosage regimens of fluoxetine in major depression.
Topics: Adult; Akathisia, Drug-Induced; Anxiety; Clinical Trials as Topic; Depressive Disorder; Dose-Respons | 1985 |
A comparative trial of fluoxetine and amitriptyline in patients with major depressive disorder.
Topics: Adult; Aged; Akathisia, Drug-Induced; Ambulatory Care; Amitriptyline; Clinical Trials as Topic; Depr | 1985 |
8 other studies available for fluoxetine and Nausea
| Article | Year |
|---|---|
Adverse events reported by anxious school refusing adolescents receiving cognitive behavioral therapy with and without fluoxetine.
Topics: Absenteeism; Adolescent; Adolescent Behavior; Anxiety Disorders; Cognitive Behavioral Therapy; Combi | 2019 |
Effect of 5-HT3 antagonists and a 5-HT(1A) agonist on fluoxetine-induced conditioned gaping reactions in rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiemetics; Autoreceptors; Conditioning, Psycholog | 2009 |
Selective serotonin reuptake inhibitors (SSRIs) in the treatment of elderly depressed patients: a qualitative analysis of the literature on their efficacy and side-effects.
Topics: 1-Naphthylamine; Aged; Anorexia; Antidepressive Agents; Depressive Disorder; Diarrhea; Fluoxetine; F | 1996 |
SSRI discontinuation syndrome treated with fluoxetine.
Topics: Aged; Akathisia, Drug-Induced; Dizziness; Drug Administration Schedule; Female; Fluoxetine; Humans; | 1998 |
Fluoxetine (Sarafem) for premenstrual dysphoric disorder.
Topics: Adult; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder; Dose-Response Relationship, Dru | 2001 |
Fluoxetine in elderly patients: is there cause for concern?
Topics: Age Factors; Aged; Ambulatory Care; Anorexia; Comorbidity; Depressive Disorder; Female; Fluoxetine; | 1992 |
Interaction of fluoxetine and pentazocine.
Topics: Adult; Anxiety; Ataxia; Drug Interactions; Fluoxetine; Humans; Hypertension; Male; Nausea; Paresthes | 1990 |
Toxic reaction following the combined administration of fluoxetine and L-tryptophan: five case reports.
Topics: Adult; Akathisia, Drug-Induced; Arrhythmias, Cardiac; Drug Interactions; Female; Fluoxetine; Humans; | 1986 |